- Home
- VRAX vs DWTX Comparison
VRAX vs DWTX Comparison
Compare VRAX & DWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- DWTX
- Stock Information
- Founded
- VRAX 2013
- DWTX 2012
- Country
- VRAX United Kingdom
- DWTX United States
- Employees
- VRAX N/A
- DWTX N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- DWTX
- Sector
- VRAX Health Care
- DWTX
- Exchange
- VRAX Nasdaq
- DWTX NYSE
- Market Cap
- VRAX 5.9M
- DWTX 5.9M
- IPO Year
- VRAX 2022
- DWTX N/A
- Fundamental
- Price
- VRAX $1.09
- DWTX $5.66
- Analyst Decision
- VRAX Strong Buy
- DWTX Strong Buy
- Analyst Count
- VRAX 1
- DWTX 1
- Target Price
- VRAX $3.00
- DWTX $10.00
- AVG Volume (30 Days)
- VRAX 300.7K
- DWTX 2.4M
- Earning Date
- VRAX 02-05-2025
- DWTX 05-14-2025
- Dividend Yield
- VRAX N/A
- DWTX N/A
- EPS Growth
- VRAX N/A
- DWTX N/A
- EPS
- VRAX N/A
- DWTX N/A
- Revenue
- VRAX $84,872.00
- DWTX N/A
- Revenue This Year
- VRAX $5,169.18
- DWTX N/A
- Revenue Next Year
- VRAX $66.97
- DWTX N/A
- P/E Ratio
- VRAX N/A
- DWTX N/A
- Revenue Growth
- VRAX 7.03
- DWTX N/A
- 52 Week Low
- VRAX $0.60
- DWTX $1.62
- 52 Week High
- VRAX $9.00
- DWTX $29.28
- Technical
- Relative Strength Index (RSI)
- VRAX 48.47
- DWTX N/A
- Support Level
- VRAX $0.91
- DWTX N/A
- Resistance Level
- VRAX $1.09
- DWTX N/A
- Average True Range (ATR)
- VRAX 0.11
- DWTX 0.00
- MACD
- VRAX 0.03
- DWTX 0.00
- Stochastic Oscillator
- VRAX 51.92
- DWTX 0.00
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.
About DWTX DOGWOOD THERAPEUTICS INC
Dogwood Therapeutics Inc formerly Virios Therapeutics Inc is a development-stage biotechnology company. It is focused advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, such as fibromyalgia (FM) and Long-COVID (LC). Its product candidates includes IMC-1 and IMC-2, IMC-1, is intended to synergistically suppress herpesvirus activation and replication with a more specific activity against the Epstein-Barr virus (herpesvirus HHV-4, IMC-2 is a combination of valacyclovir and celecoxib.